The McGill RAAS-COVID-19 Trial

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

April 1, 2021

Study Completion Date

April 17, 2021

Conditions
COVID-19Cardiovascular Diseases
Interventions
OTHER

Temporarily holding the RAAS inhibitor [intervention]

Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.

OTHER

RAAS inhibitor [continued standard of care]

No intervention, Continuation RAAS inhibitor \[continued standard of care\].

Trial Locations (1)

H4A 3J1

Muhc-Rimuhc, Montreal

All Listed Sponsors
collaborator

Jewish General Hospital (Montreal, Quebec, Canada)

UNKNOWN

collaborator

Montreal General Hospital (Montreal, Quebec, Canada)

UNKNOWN

collaborator

Université de Lorraine, Centre d'Investigation Clinique- Plurithématique Inserm

UNKNOWN

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT04508985 - The McGill RAAS-COVID-19 Trial | Biotech Hunter | Biotech Hunter